

---

---

THE GENERAL ASSEMBLY OF PENNSYLVANIA

---

HOUSE BILL

No. 593 Session of  
2021

---

INTRODUCED BY ZABEL, HANBIDGE, GALLOWAY, McNEILL, FREEMAN,  
T. DAVIS, DeLUCA, FRANKEL, O'MARA, WEBSTER, GUENST,  
PISCIOTTANO, KINKEAD, SHUSTERMAN, MADDEN, KENYATTA AND  
HOWARD, FEBRUARY 24, 2021

---

REFERRED TO COMMITTEE ON HEALTH, FEBRUARY 24, 2021

---

AN ACT

1 Providing for Pharmaceutical Manufacturing Prohibited Gifts Act.

2 The General Assembly of the Commonwealth of Pennsylvania

3 hereby enacts as follows:

4 Section 1. Short title.

5 This act shall be known and may be cited as the

6 Pharmaceutical Manufacturer Prohibited Gifts Act.

7 Section 2. Definitions.

8 The following words and phrases when used in this act shall

9 have the meanings given to them in this section unless the

10 context clearly indicates otherwise:

11 "Allowable expenditures." The term includes:

12 (1) Payment to the sponsor of a significant educational,  
13 medical, scientific or policymaking conference or seminar,  
14 provided:

15 (i) the payment is not made directly to a health  
16 care professional or pharmacist;

1 (ii) funding is used solely for bona fide  
2 educational purposes, except that the sponsor may, in the  
3 sponsor's discretion, apply some or all of the funding to  
4 provide meals and other food for all conference  
5 participants; and

6 (iii) all program content is objective, free from  
7 industry control and does not promote specific products.

8 (2) Honoraria and payment of the expenses of a health  
9 care professional who serves on the faculty at a bona fide  
10 significant educational, medical, scientific or policymaking  
11 conference or seminar, provided:

12 (i) there is an explicit contract with specific  
13 deliverables that are restricted to medical issues, not  
14 marketing activities; and

15 (ii) consistent with Federal law, the content of the  
16 presentation, including slides and written materials, is  
17 determined by the health care professional.

18 (3) For a bona fide clinical trial:

19 (i) gross compensation for the location or locations  
20 involved;

21 (ii) direct salary support per principal  
22 investigator and other health care professionals per  
23 year; and

24 (iii) expenses paid on behalf of investigators or  
25 other health care professionals paid to review the  
26 clinical trial.

27 (4) A research project or bona fide marketing research  
28 project that constitutes a systematic investigation, is  
29 designed to develop or contribute to general knowledge and  
30 reasonably can be considered to be of significant interest or

1 value to scientists or health care professionals working in  
2 the particular field of inquiry, including:

3 (i) gross compensation;

4 (ii) direct salary support per health care  
5 professional; and

6 (iii) expenses paid on behalf of each health care  
7 professional.

8 (5) Payment or reimbursement for the reasonable  
9 expenses, including travel and lodging-related expenses,  
10 necessary for technical training of individual health care  
11 professionals on the use of a device if the commitment to  
12 provide the expenses and the amounts or categories of  
13 reasonable expenses to be paid are described in a written  
14 agreement between the health care provider and the  
15 manufacturer.

16 (6) Royalties and licensing fees paid to health care  
17 providers in return for contractual rights to use or purchase  
18 a patented or otherwise legally recognized discovery for  
19 which the health care provider holds an ownership right.

20 (7) The payment of the reasonable expenses of an  
21 individual related to the interview of the individual by a  
22 manufacturer of prescribed products in connection with a bona  
23 fide employment opportunity or for health care services on  
24 behalf of an employee of the manufacturer.

25 (8) Sponsorship of an educational program offered by a  
26 device manufacturer at a national or regional professional  
27 society meeting at which programs accredited by the  
28 Accreditation Council for Continuing Medical Education, or a  
29 comparable professional accrediting entity, are also offered,  
30 provided:

1 (i) no payment is made directly to a health care  
2 professional or pharmacist; and

3 (ii) the funding is used solely for bona fide  
4 educational purposes, except that the manufacturer may  
5 provide meals and other food for program participants.

6 (9) Items with a total combined retail value, in any  
7 calendar year, of not more than \$50.

8 (10) Payment to a practitioner for participation in bona  
9 fide marketing research conducted by a third party, if the  
10 payments are made by the third party and the sponsoring  
11 manufacturer is not informed of the identity of the  
12 participating practitioner.

13 (11) Other reasonable fees, payments, subsidies or other  
14 economic benefits provided by a manufacturer of prescribed  
15 products at fair market value.

16 "Bona fide clinical trial." An FDA-reviewed clinical trial  
17 that constitutes research, as that term is defined in 45 CFR §  
18 46.102 (relating to definitions for purposes of this policy),  
19 and reasonably can be considered to be of interest to scientists  
20 or health care professionals working in the particular field of  
21 inquiry.

22 "Bona fide marketing research." The collection and analysis  
23 of data regarding opinions, needs, awareness, knowledge, views,  
24 experiences and behaviors of a population, through the  
25 development and administration of surveys, interviews, focus  
26 groups, polls, observation or other research methodologies, in  
27 which no sales, promotional or marketing efforts are involved  
28 and through which there is no attempt to influence a  
29 participant's attitudes or behavior.

30 "Clinical trial." Any study assessing the safety or efficacy

1 of prescribed products administered alone or in combination with  
2 other prescribed products or other therapies, or assessing the  
3 relative safety or efficacy of prescribed products in comparison  
4 with other prescribed products or other therapies.

5 "Device." As defined in section 201 of the Federal Food,  
6 Drug, and Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.).

7 "Free clinic." A health care facility operated by a  
8 nonprofit private entity that:

9 (1) in providing health care, does not accept  
10 reimbursement from any third-party payor, including  
11 reimbursement from any insurance policy, health plan or  
12 Federal or State health benefits program that is individually  
13 determined;

14 (2) in providing health care, either:

15 (i) does not impose charges on patients to whom  
16 service is provided; or

17 (ii) imposes charges on patients according to the  
18 patient's ability to pay;

19 (3) may accept patients' voluntary donations for health  
20 care service provision; and

21 (4) is licensed or certified to provide health care  
22 services in accordance with the laws of this Commonwealth.

23 "Gift." Means:

24 (1) anything of value provided for free to a health care  
25 provider; or

26 (2) except as provided for allowable expenditures, any  
27 payment, food, entertainment, travel, subscription, advance,  
28 service or anything else of value provided to a health care  
29 provider, unless:

30 (i) it is an allowable expenditure; or

1 (ii) the health care provider reimburses the cost at  
2 fair market value.

3 "Health benefit plan administrator." The person or entity  
4 who sets formularies on behalf of an employer or health insurer.

5 "Health care professional." The following:

6 (1) A person who is authorized by law to prescribe or to  
7 recommend prescribed products, who regularly practices in  
8 this Commonwealth, and who either is licensed by the  
9 Commonwealth to provide or is otherwise lawfully providing  
10 health care in this Commonwealth.

11 (2) A partnership or corporation made up of the persons  
12 described in paragraph (1).

13 (3) An officer, employee, agent or contractor of a  
14 person described in paragraph (1) who is acting in the course  
15 and scope of employment, of an agency or of a contract  
16 related to or supportive of the provision of health care to  
17 individuals.

18 (4) The term shall not include a person described in  
19 paragraph (1) who is employed solely by a manufacturer.

20 "Health care provider." A health care professional,  
21 hospital, nursing home, pharmacist, health benefit plan  
22 administrator or any other person authorized to dispense or  
23 purchase for distribution prescribed products in this  
24 Commonwealth. The term does not include a hospital foundation  
25 that is organized as a nonprofit entity separate from a  
26 hospital.

27 "Manufacturer." A pharmaceutical, biological product or  
28 device manufacturer or any other person who is engaged in the  
29 production, preparation, propagation, compounding, processing,  
30 marketing, packaging, repackaging, distributing or labeling of

1 prescribed products. The term does not include:

2 (1) a wholesale distributor of biological products or a  
3 retailer or a pharmacist licensed under the act of September  
4 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act; or

5 (2) a manufacturer whose only prescribed products are  
6 classified as Class I by the United States Food and Drug  
7 Administration, are exempt from premarket notification under  
8 section 510(k) of the Federal Food, Drug, and Cosmetic Act  
9 and are sold over-the-counter without a prescription.

10 "Marketing." Includes promotion, detailing or any activity  
11 that is intended to be used or is used to influence sales or  
12 market share or to evaluate the effectiveness of a professional  
13 sales force.

14 "Pharmaceutical manufacturer." Any entity that is engaged in  
15 the production, preparation, propagation, compounding,  
16 conversion or processing of prescription drugs, whether directly  
17 or indirectly by extraction from substances of natural origin,  
18 independently by means of chemical synthesis or by a combination  
19 of extraction and chemical synthesis or any entity engaged in  
20 the packaging, repackaging, labeling, relabeling or distribution  
21 of prescription drugs. The term does not include a wholesale  
22 distributor of prescription drugs, a retailer or a pharmacist  
23 licensed under the Pharmacy Act.

24 "Prescribed product." A drug as defined in section 201 of  
25 the Federal Food, Drug, and Cosmetic Act, a compound drug or  
26 drugs, a device as defined in this section, a biological product  
27 as defined in section 351 of the Public Health Service Act (58  
28 Stat. 682, 42 U.S.C. § 201 et seq.) for human use or a  
29 combination product as defined in 21 CFR § 3.2(e) (relating to  
30 definitions). The term does not include prescription eyeglasses,

1 prescription sunglasses or other prescription eyewear.

2 "Regularly practices." To practice at least periodically  
3 under contract with, as an employee of or as the owner of a  
4 medical practice, health care facility, nursing home, hospital  
5 or university located in this Commonwealth.

6 "Sample." A unit of a prescription drug, biological product  
7 or device that is not intended to be sold and is intended to  
8 promote the sale of the drug, product or device. The term  
9 includes starter packs and coupons or other vouchers that enable  
10 an individual to receive a prescribed product free of charge or  
11 at a discounted price. The term does not include prescribed  
12 products distributed free of charge or at a discounted price  
13 under a manufacturer-sponsored or manufacturer-funded patient  
14 assistance program.

15 "Significant educational, scientific or policymaking  
16 conference or seminar." An educational, scientific or  
17 policymaking conference or seminar that:

18 (1) is accredited by the Accreditation Council for  
19 Continuing Medical Education or a comparable organization or  
20 is presented by an approved sponsor of continuing education,  
21 provided that the sponsor is not a manufacturer of prescribed  
22 products; and

23 (2) offers continuing education credit, features  
24 multiple presenters on scientific research or is authorized  
25 by the sponsor to recommend or make policy.

26 Section 3. Expenditures by manufacturers of prescribed  
27 products.

28 (a) Prohibition.--A manufacturer of a prescribed product or  
29 any wholesale distributor of devices, or any agent thereof, may  
30 not offer or give any gift to a health care provider.



1 (b) Exception.--The prohibition under subsection (a) shall  
2 not apply to any of the following:

3 (1) Samples of a prescribed product or reasonable  
4 quantities of an over-the-counter drug, a nonprescription  
5 device, an item of nonprescription durable medical equipment,  
6 an item of medical food as defined in section 360ee(b)(3) of  
7 the Federal Food, Drug, and Cosmetic Act (52 Stat. 1040, 21  
8 U.S.C. § 301 et seq.) or infant formula as defined in section  
9 201(z) of the Federal Food, Drug, and Cosmetic Act, provided  
10 to a health care provider for free distribution to patients.

11 (2) The loan of a device for a short-term trial period,  
12 not to exceed 120 days, to permit evaluation of a device by a  
13 health care provider or patient.

14 (3) The provision of reasonable quantities of device  
15 demonstration or evaluation units to a health care provider  
16 to assess the appropriate use and function of the product and  
17 determine whether and when to use or recommend the product in  
18 the future.

19 (4) The provision, distribution, dissemination or  
20 receipt of peer-reviewed academic, scientific or clinical  
21 articles or journals and other items that serve a genuine  
22 educational function provided to a health care provider for  
23 the benefit of patients.

24 (5) Scholarship or other support for medical students,  
25 residents or fellows to attend a significant educational,  
26 scientific or policymaking conference or seminar of a  
27 national, regional or specialty medical or other professional  
28 association if the recipient of the scholarship or other  
29 support is selected by the association.

30 (6) Rebates and discounts for prescribed products

1 provided in the normal course of business.

2 (7) Labels approved by the Food and Drug Administration  
3 for prescribed products.

4 (8) The provision to a free clinic of financial  
5 donations or of free:

6 (i) prescription drugs;

7 (ii) over-the-counter drugs;

8 (iii) devices;

9 (iv) biological products;

10 (v) combination products;

11 (vi) medical food;

12 (vii) infant formula; or

13 (viii) medical equipment or supplies.

14 (9) Prescribed products distributed free of charge or at  
15 a discounted price pursuant to a manufacturer-sponsored or  
16 manufacturer-funded patient assistance program.

17 (10) Fellowship salary support provided to fellows  
18 through grants from manufacturers of prescribed products,  
19 provided:

20 (i) the grants are applied for by an academic  
21 institution or hospital;

22 (ii) the institution or hospital selects the  
23 recipient fellows;

24 (iii) the manufacturer imposes no further demands or  
25 limits on the institution's, hospital's or fellow's use  
26 of the funds; and

27 (iv) fellowships are not named for a manufacturer  
28 and no individual recipient's fellowship is attributed to  
29 a particular manufacturer of prescribed products.

30 (11) The provision of coffee or other snacks or

1 refreshments at a booth at a conference or seminar.

2 (c) Fee, payment, subsidy or other economic benefit  
3 prohibited.--Except for allowable expenditures, no manufacturer  
4 or other entity on behalf of a manufacturer shall provide any  
5 fee, payment, subsidy or other economic benefit to a health care  
6 provider in connection with the provider's participation in  
7 research.

8 (d) Penalties.--The Attorney General or appropriate legal  
9 authority may bring legal action for a violation of this act and  
10 may impose on a manufacturer that violates the provisions of  
11 this act a civil penalty of not more than \$10,000 per violation.  
12 Each unlawful gift shall constitute a separate violation. In any  
13 action brought under this act, the Attorney General or  
14 appropriate legal authority shall have the same authority to  
15 investigate and to obtain remedies as if the action were brought  
16 under the act of December 17, 1968 (P.L.1224, No.387), known as  
17 the Unfair Trade Practices and Consumer Protection Law.  
18 Section 4. Effective date.

19 This act shall take effect in 60 days.